ASP Isotopes

ASP Isotopes is pre-revenue as of the latest filings. The company expects to generate revenue through long-term offtake agreements once its enrichment facilities become operational — selling physical isotopes to nuclear-reactor developers and radiopharmaceutical manufacturers. There is no royalty or streaming model; ASP owns and operates the production assets directly. The company has funded operations through equity offerings, including a $33M registered direct offering in October 2023 (per the firm, October 2023).

The company uses two primary technologies: the Quantum Laser Enrichment (QLT) process for stable medical isotopes like molybdenum-100, and the Aerodynamic Separation Process (ASP) for uranium enrichment. Both are licensed from third-party research institutions and subject to regulatory oversight by the US Nuclear Regulatory Commission and South African nuclear authorities. The QLT process was originally developed for silicon-28 and is now being adapted for medical isotopes, while the ASP technology is a cyclonic gaseous diffusion alternative to gas centrifuges.

Yes — in the HALEU market specifically. The firm's South African ASP facility is designed to produce HALEU for advanced reactor developers seeking a supply chain independent of Rosatom, which currently controls roughly 46% of global enrichment capacity (public record). ASP positions itself as a Western-aligned commercial alternative, though it operates at a far smaller planned scale. Its medical isotope strategy does not overlap significantly with Russian state entities.

The two processes share a corporate parent but operate as technologically distinct silos with different regulatory pathways and customer sets. The QLT laser facility produces stable isotopes for the medical imaging and cancer-therapy supply chain. The ASP aerodynamic facility targets nuclear fuel isotopes, principally HALEU. The dual-track structure acts as an internal hedge — medical isotopes follow healthcare regulatory frameworks, while the nuclear business is subject to non-proliferation and fuel-cycle licensing.

The firm licenses its core separation technologies from research institutions and specialized engineering firms. The QLT laser-enrichment intellectual property is based on laser-isotope separation work originally developed in university and commercial labs for semiconductor materials. The ASP process is a proprietary aerodynamic separation method distinct from centrifuge technology. Full licensor names have not been disclosed in public filings, though the company indicates the underlying IP is subject to exclusive or long-term licensing agreements for nuclear and medical applications.

Regulatory risk is among the highest for the enrichment sector. The company requires Nuclear Regulatory Commission licensing for its US facilities and National Nuclear Regulator authorization in South Africa. Delays in licensing have historically determined project viability. ASP's public-company structure subjects these risks to securities disclosures, offering investors visibility that private enrichment ventures typically lack. The independent board appointed in 2024 includes former nuclear regulators, a signal of priority on licensing milestones.

No. ASP Isotopes is a publicly traded operating company, not a fund manager. It raises capital via NASDAQ equity offerings and deploys it directly into wholly owned enrichment facilities. There is no commingled vehicle, no third-party limited partners, and no fund-of-funds structure. The altss profile classification as 'Asset Manager' reflects the firm's capital deployment into hard-asset enrichment infrastructure, not a traditional asset-management mandate.